Welcome!

News Feed Item

Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation


Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation

Summary

GBI Research has released a new pharmaceutical report, "Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation". This highly competitive market is saturated with multiple targeted monoclonal Antibody (mAb) therapies and small molecules, yet more of these treatments are expected to enter the market over the next few years. Despite this, the current developmental pipeline is highly innovative beyond these me-too products and incremental innovations and promises a number of first-in-class products across all stages. These new developments are driven by improvements in the understanding of signaling pathways and underlying disease mechanisms of Rheumatoid Arthritis (RA). These highly innovative products are expected to increase the diversity of available products, in terms of mechanism of action over the coming decade and are likely to have a significant impact on the dynamics of the clinical and commercial landscape.

The market is also characterized by high activity in licensing and co-development deals. In particular, there is sustained commercial interest in pipeline biologic therapies with a range of molecular targets. There is also considerable interest in small molecule inhibitors of intracellular kinases despite their clinical performances not being as well established as biologics or mAbs.

Scope

- The report analyzes the RA pipeline and strategic alliance landscape with particular emphasis on first-in-class programs.
- A brief introduction to RA, including symptoms, pathophysiology, and an overview of the pharmacotherapy
- Highlights of the changing molecular target landscape between marketed and pipeline products with particular focus on innovation
- A comprehensive review of first-in-class pipeline therapies; the pipeline is analyzed by Phase distribution, molecule type, molecular target, and administration route
- Identification and assessment of first-in-class molecular targets highlighting early-stage programs with clinical utility that has yet to be evaluated, as well as an in-depth literature review of novel molecular targets
- Assessment of the licensing and co-development deals for RA therapeutics

Reasons to buy

The report will assist business development strategies of companies who wish to develop RA therapies with improved benefits to existing treatments. In addition, this report will be of interest to companies seeking to expand pipeline portfolios through licensing agreements and co-development deals allowing them to -
- Understand the overall focal shifts in therapeutic molecular targets of RA treatments
- Identify first-in-class product development and understand the therapeutic and commercial prospects of first-in-class developmental programs based on available animal model data
- Assess the value of products benchmarked against licensed and co-developed therapeutic programs
- Spot first-in-class programs that are potentially available for licensing and co-development deals

Table of Contents

1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 The Case for Innovation 8
2.1.1 Growing Opportunities for Biologic Products 8
2.1.2 Diversification of Molecular Targets 8
2.1.3 Innovative First-in-class Product Developments Remain Attractive 9
2.1.4 Changes in the Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Niche Indications 9
2.1.5 Sustained Innovation 10
3 Clinical and Commercial Landscape 11
3.1 Disease Overview 11
3.1.1 Disease Symptoms 12
3.1.2 Environmental Factors and Genetic Predisposition 12
3.1.3 Disease Pathophysiology 12

3.1.4 Pharmacotherapy Algorithm 13
3.2 Overview of Marketed Products for Rheumatoid Arthritis 14
3.3 Molecular Type Analysis 15
3.4 Molecular Target Analysis 16
3.4.1 Intracellular Therapeutic Targets 16
3.4.2 Membrane Therapeutic Targets 17
3.4.3 Extracellular Targets 17
3.5 Innovative Products in the RA Market 17
3.6 Efficacy and Safety of Marketed Products 20
3.7 Current Unmet Needs 22
4 Assessment of Pipeline Product Innovation 23
4.1 Rheumatoid Arthritis Pipeline by Molecule Type, Phase and Therapeutic Targets 23
4.2 Frequently Targeted Intracellular Kinases 25
4.2.1 p38 Kinase 25
4.2.2 MAPK 25
4.2.3 JAK 25
4.2.4 Spleen Tyrosine Kinase (Syk) 25
4.3 Frequently Targeted Cytokines and Receptors 26
4.3.1 TNF-? 26
4.3.2 Toll-Like Receptors 26
4.3.3 B Lymphocyte Stimulator 26

4.4 Efficacy and Safety of Pipeline Products 27
4.5 Comparative Distribution of Programs between the RA Market and Pipeline by Therapeutic Target Family 29
4.6 First-in-class Pipeline Programs Targeting Novel Molecule Targets 31
5 First-in-Class Target and Pipeline Program Evaluation 37
5.1 Cytokines and Receptors 37
5.1.1 Pipeline Programs which Target HMGB-1 37
5.1.2 Pipeline Programs which Target IL-10 Receptor 42
5.1.3 Pipeline Programs which Target HSP 60 46
5.1.4 Pipeline Programs which Target Interleukins 15 and 16 49
5.1.5 Pipeline programs which Target Macrophage Migration Inhibitory Factor (MIF) 52
5.2 Integrins 55
5.2.1 Pipeline Programs which Target Cadherin-11 55

5.2.2 Pipeline Programs which Target ?1?1 Integrin (Very Late Antigen-1) 56
5.2.3 Pipeline Programs which Target Vascular Adhesion Protein-1 (VAP-1) 58
5.3 Proteases 59
5.3.1 Pipeline Programs which Target Cathepsin S 59
5.4 Nuclear Receptors 61
5.4.1 Pipeline Programs which Target RAR-Related Orphan Receptor (ROR) 61
5.4.2 Pipeline Programs which Target Nuclear Receptor Related 1 Protein 63
5.5 Intracellular Kinases 64
5.5.1 Pipeline Programs which Target Interleukin 1 Receptor Associated Kinase 4 64
5.6 Ion Channels 66
5.6.1 Pipeline Programs which Target Calcium Release Activated Channels 66
5.7 Others 68
5.7.1 Pipeline Programs which Target F1F0 ATP Synthase 68

5.7.2 Pipeline Programs which Target Immunoproteosome Subunit 7 (IMP7) 69
5.8 Conclusion 71
6 Deals and Strategic Consolidations 73
6.1 Licensing Deals 73
6.2 Co-development Deals 86
6.3 First-in-Class Programs which have not been involved in Licensing or Co-Development Deals 98
7 Appendix 99
7.1 Abbreviations 99
7.2 Methodology 102
7.3 References 102
7.4 References for Figures 5 and 8 109
7.5 Contact Us 111
7.6 Disclaimer 112

List of Tables

Table 1: Pipeline, Global, First-in-class, High Mobility Box Protein-1 Inhibitors 39
Table 2: Pipeline, Global, First-in-class IL-10 Receptor 44
Table 3: Overview of Pipeline, Global, First-in-class IL-10 Receptor Activator 46
Table 4: Pipeline, Global, First-in-class Inhibitors of HSP60 48
Table 5: Overview of Pipeline, Global, First-in-class Inhibitors of HSP60 49
Table 6: Pipeline, Global, First-in-class Inhibitors of IL-15 50
Table 7: Pipeline, Global, First-in-class Inhibitors of MIF 54
Table 8: Pipeline, Global, First-in-class Inhibitors of Very Late Antigen-1 57
Table 9: Overview of Pipeline, Global, First-in-class Inhibitors of Very Late Antigen-1 57
Table 10: Pipeline, Global, First-in-class Modulators of Cathepsin S 60
Table 11: Pipeline, Global, First-in-class Modulators of NURR-1 63
Table 12: Pipeline, Global, First-in-class modulators of Interleukin-1 Associated Kinase 4 65
Table 13: Pipeline, Global, First-in-class Modulators of Immunoproteosome Subunit 7 70
Table 14: Overview of Pipeline, Global, First-in-class Modulators of Immunoproteosome Subunit 7 71
Table 15: References for Figures 5 and 8 109

List of Figures

Figure 1: American College of Rheumatology Treatment Guidelines. 2012 14
Figure 2: Rheumatoid Arthritis, Global, Marketed Products, Part 1 15
Figure 3: Rheumatoid Arthritis, Global, Marketed Products, Part 2 16
Figure 4: Rheumatoid Arthritis, Global, Innovative Marketed Products 19
Figure 5: Rheumatoid Arthritis, Global, Marketed Products, Comparative Efficacy and Safety 21
Figure 6: Rheumatoid Arthritis, Global, Pipeline by Molecule Type, Phase and Therapeutic Targets 24

Figure 7: Rheumatoid Arthritis, Global, Pipeline 27
Figure 8: Rheumatoid Arthritis, Global, Pipeline Products, Comparative Efficacy and Safety 28
Figure 9: Rheumatoid Arthritis, Global, Pipeline and Marketed Products 30
Figure 10: Rheumatoid Arthritis, Global, Pipeline, First-in-class Products 32
Figure 11: Rheumatoid Arthritis, Global, Pipeline, First-in-class Products in the RA Pipeline, Part-1 34
Figure 12: Rheumatoid Arthritis, Global, Pipeline, First-in-class Products in the RA Pipeline, Part-2 35
Figure 13: Pipeline, Global, First-in-class High Mobility Box Protein-1 Inhibitors 41
Figure 14: Pipeline, Global, First-in-class Inhibitors of IL-15 52
Figure 15: Pipeline, Global, First-in-class Inhibitors of MIF 55

Figure 16: Pipeline, Global, First-in-class Inhibitors Cadherin-11 56
Figure 17: Pipeline, Global, First-in-class Inhibitors of Vascular Adhesion Protein-1 58
Figure 18: Pipeline, Global, First-in-class Inhibitors of Cathepsin S 61
Figure 19: Pipeline, Global, First-in-class Modulators of RAR-related Orphan Receptors 62
Figure 20: Pipeline, Global, First-in-class Modulators of Interleukin 1 Associated Kinase 4 66
Figure 21: Pipeline, Global, First-in-class modulators of Calcium Release Activated Channels 67
Figure 22: Pipeline, Global, First-in-class Modulators of F1F0 ATP Synthase 68
Figure 23: Rheumatoid Arthritis, Global, Licensing Agreements, 2006–September 2013, (A) 73
Figure 24: Rheumatoid Arthritis, Global, Licensing Agreements, 2006–September 2013,(B) 75
Figure 25: Rheumatoid Arthritis, Global, Licensing Agreements, 2006–September 2013, (C) 76
Figure 26: Rheumatoid Arthritis, Global, Licensing Agreements, 2006–September 2013, (D) 78
Figure 27: Rheumatoid Arthritis, Global, Licensing Agreements, 2006–September 2013, (E) 79
Figure 28: Rheumatoid Arthritis, Global, Licensing Agreements, 2006–September 2013, (F) 81
Figure 29: Rheumatoid Arthritis, Global, Licensing Agreements, First-in-class Programs, 2006 -September 2013, (A) 82
Figure 30: Rheumatoid Arthritis, Global, Licensing Agreements, First-in-class Programs, 2006–September 2013, (B) 83
Figure 31: Rheumatoid Arthritis, Global, Licensing Agreements, First-in-class Programs, 2006–September 2013, (C) 84
Figure 32: Rheumatoid Arthritis, Global, Licensing Agreements, First-in-class Programs, 2006–September 2013, (D) 85

Figure 33: Rheumatoid Arthritis, Global, Co-development Deals, 2006–September 2013, (A) 86
Figure 34: Rheumatoid Arthritis, Global, Co-development Deals, 2006–September 2013, (B) 88
Figure 35: Rheumatoid Arthritis, Global, Co-development Deals, 2006–September 2013, (C) 89
Figure 36: Rheumatoid Arthritis, Global, Co-development Deals, 2006–September 2013, (D) 91
Figure 37: Rheumatoid Arthritis, Global, Co-development Deals, 2006–September 2013, (E) 92
Figure 38: Rheumatoid Arthritis, Global, Co-development Deals, 2006–September 2013, (F) 93
Figure 39: Rheumatoid Arthritis, Global, Co-development Deals, September First-in-class Programs, 2006–September 2013, (A) 94
Figure 40: Rheumatoid Arthritis, Global, Co-development Deals, September First-in-class Programs, 2006–September 2013, (B) 95
Figure 41: Rheumatoid Arthritis, Global, Co-development Deals, 2006-2013 (September), First-in-class Programs,(C) 96
Figure 42: Rheumatoid Arthritis, Global, Co-development Deals, 2006-2013 (September), First-in-class Programs, (D) 97
Figure 43: Rheumatoid Arthritis, Global, First-in-class Programs with no Recorded Prior Deal Involvement, 2006–2013 98

Read the full report:
Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation
http://www.reportbuyer.com/pharma_healthcare/diseases/frontier_pharma_rheumatoid_arthritis_identifying_commercializing_first_in_class_innovation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com  
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
SYS-CON Events announced today that StarNet Communications will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. StarNet Communications’ FastX is the industry first cloud-based remote X Windows emulator. Using standard Web browsers (FireFox, Chrome, Safari, etc.) users from around the world gain highly secure access to applications and data hosted on Linux-based servers in a central data center. ...
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
StarNet Communications Corp has announced the addition of three Secure Remote Desktop modules to its flagship X-Win32 PC X server. The new modules enable X-Win32 to safely tunnel the remote desktops from Linux and Unix servers to the user’s PC over encrypted SSH. Traditionally, users of PC X servers deploy the XDMCP protocol to display remote desktop environments such as the Gnome and KDE desktops on Linux servers and the CDE environment on Solaris Unix machines. XDMCP is used primarily on comp...
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...